

Index

A

- Accelerated gastric emptying, 74, 95
- Achalasia, 42
- Acid neutralization, 59
- Acinar atrophy, 226
- Acoustic radiation force impulse (ARFI) elastography, 322, 323
- AIC test, 5
- Acute erosive esophagitis, 70
- Acute hyperglycemia, 22, 36, 116, 153, 156
- Acute necrotic collections (ANC), 219
- Acute pancreatitis (AP), 234, 235, 239, 249–253
 - classification, 216, 217
 - complications, 218
 - course of disease, 220, 221
 - diagnosis, 216, 217, 239
 - epidemiology, 214
 - etiology, 215
 - laboratory test
 - lipase, 234
 - serum amylase, 234
 - serum lipase, 235
 - local complications, 217, 218
 - management of, 250
 - pathogenesis, 215, 216
 - systemic complications, 220
 - treatment
 - analgesia, 251
 - antibiotics, 251
 - biliary decompression, 253
 - fluid resuscitation, 249, 250
 - invasive treatment, 252
 - management of, 249
 - nutrition, 251
- Adipokines, 279, 280
- Adiponectin, 306
- Adipose tissue dysfunction, 216, 287
- Adult-onset diabetes, *see* Type 2 diabetes
- Advanced glycation end products (AGEs), 32, 118, 153, 177
- Afferent (sensory) pathways, 9
- Alanine aminotransferase (ALT), 283, 288
- Albumin, 269
- Alcohol dehydrogenase (ADH), 272
- Alcoholic fatty liver disease (AFLD), 283
- Aldehyde dehydrogenase (ALDH), 272
- American Cancer Society (ACS), 263
- Aminotransferase levels, 320
- Amoxicillin, 193
- Amyloidosis, 129
- Anal sphincter system, 146
- Analgesia, 251
- Anorectal function, 154–156
 - anatomy, 146
 - anorectal manometry, 148
 - anorectal sensory system, 147
 - defecography/evacuation proctography, 148
 - diabetes mellitus
 - acute hyperglycemia, 156
 - diabetic neuropathy, 154
 - nitric oxide level, 155
 - electromyography, 148
 - endoanal ultrasonography, 148
 - intrinsic/enteric nervous system, 147
 - local neuronal reflexes, 147
 - pelvic floor, 146
 - PNTML test, 148

- Anorectal inhibitory reflex, 184
 Anorectal manometry, 148, 186
 Antibiotics, 251
 Appetite suppression, 63
 Arcuate nucleus of the hypothalamus (ARC), 14
 American Society of Clinical Oncology (ASCO), 259–261
 Aspartate aminotransferase (AST), 283, 288
 Atherosclerotic plaque, 31
 Auerbach's plexus, *see* Myenteric plexus
 Autoimmune destruction, 4
 Autoimmune diseases, 42, 50
 Autoimmune hepatitis, 44
 Autonomic nervous system (ANS)
 DAN, 12
 enteric nervous system, 8
 extrinsic nervous system, 9, 48
 food intake and digestion, 11
 ICC, 9
 neural control, 11
 parasympathetic, 48
 sympathetic, 48
 Autonomic neuropathy, 36, 84, 116, 227
- B**
- Balloon expulsion test, 186
 Balthazar classification, 238
 Barrett's esophagus, 85
 Basal insulin, 6
 Bile acid metabolism, 271, 272
 Bile acid–FXR axis, 334, 335
 Bile salt diarrhea, 133
 Biliary decompression, 253
 Biliary pancreatitis, 253
 Biliary stenosis, 255
 Bilirubin
 alcohol, 272
 ammonium, 273
 drug metabolism, 272, 273
 Biofeedback therapy, 193, 196
 Bowel rest, 251
 Brunner's glands, 108
 Brush border hydrolyases, 106
- C**
- Candida esophagitis
 complications, 71
 diagnosis, 71
 glycemic control, 70
 pathophysiological plausibility, 71
 symptoms, 70
 treatment, 71
 Candidiasis, 56, 92
 Carbohydrate malabsorption, 181
 Carbohydrate metabolism, 270
 Carcinoembryonic antigen (CEA), 245
 Cardiovascular disease (CVD), 290, 291, 298, 300, 301
 13C-breath tests, 133
 Celiac disease (CD), 127–129, 207
 Chemoradiotherapy (CRT), 260
 Chicago classification, 85
 Child–Pugh–Turcotte (CPT) score, 291
 Cholecystokinin (CCK), 16, 48, 206, 207, 235
 Cholestyramine, 196
 Chronic diarrhea, 178, 228
 Chronic kidney disease (CKD), 290
 Chronic pancreatitis (CP), 181, 238, 240, 242, 253–255
 diagnosis
 EUS, 242, 243
 MRI, 240
 Rosemont classification, 242
 US, 238
 symptom of, 253
 treatment
 biliary stricture management, 254, 255
 endoscopic management and surgery, 254
 medications and lifestyle modifications in pain management, 253, 254
 Chyme, 103
 Cirrhosis, 296–298, 300–302, 325
 clinical approach to patients, 292
 course of NAFLD, 290, 291
 interventions and treatment options, 293–295
 liver transplantation
 de novo or recurrent NAFLD, 301, 302
 evaluation for, 296–298
 indications, 296
 outcomes, 298, 300, 301
 patients with decompensated liver cirrhosis, 292
 CK-18, 320
 Clonidine, 193
 Clusters of differentiation (CD), 42
 Coefficient of fat absorption (CFA), 208

- Colon, 149–154, 166–174
 anatomy, 164–165
 colonic transit time, 153–154
 constipation
 AGEs, 171
 clinical presentation, 172
 enteric neural regulation, 172
 epidemiology, 170
 etiology, 171
 oxidative stress, 171
 primary causes, 170
 Rome IV diagnostic criteria, 170
 secondary causes, 170
 diabetes mellitus
 clinical manifestations, 149
 colorectal cancer cells, 153
 diabetic autonomic neuropathy, 150
 enteric nervous system, 150
 histomorphological changes, 152
 interstitial cells of Cajal, 151
 pathological factors, 150
 diarrhea
 clinical presentation, 169
 epidemiology, 166–168
 pathophysiology, 168–169
 fecal incontinence
 clinical presentation, 174
 epidemiology, 172–173
 pathophysiology, 173–174
 functional anatomy, 146
 Colonic function
 colonic motility studies, 149
 radiographic markers, 149
 scintigraphy, 149
 wireless motility capsule, 149
 Colonic motility studies, 149
 Colonic transit time (CTT), 148
 definition, 149
 diabetes mellitus, 153
 Colorectal cancer (CRC), 182
 Colostomy, 197
 Combination injectable therapy, 6
 Common bile duct (CBD) stones, 253
 Computed tomography (CT), 238, 239, 323, 324
 Constipation, 36, 182–184, 194, 195
 AGEs, 171
 causes of, 178, 182
 clinical presentation, 172
 enteric neural regulation, 172
 epidemiology, 170
 etiology, 171
 evaluation of patient, 182–184
 barium radiographs, 183
 colonic manometry, 184
 colonoscopy, 183
 contrast enema examination, 183
 digital examination, 182
 endoscopy procedure, 182
 multiple-capsule technique, 183
 patient history and physical examination, 182
 radiology procedures, 183
 radiopaque markers, 183
 rectal barostat test, 184
 scintigraphy, 183
 single-capsule technique, 183
 wireless motility capsule, 184
 management
 defecatory dysfunction, 195
 dietary measures, 194
 glycemic control, 194
 lactulose, 194
 osmotic agents, 194
 patient education, 194
 saline laxatives, 194
 sorbitol, 194
 stimulant laxatives, 194
 oxidative stress, 171
 primary causes, 170
 Rome IV diagnostic criteria, 170
 secondary causes, 170
 Contrast-enhanced EUS (CE-EUS), 241
 Controlled attenuation parameter (CAP), 323
 Coproculture, 180
 Crohn's disease, 44
 Crypts of Lieberkühn, 108
 Cystic fibrosis transmembrane conductance regulator (CFTR), 108
 Cytochrome P450 2E1 (CYP2E1), 272
 Cytokeratin-18 (CK-18), 320
 Cytokine receptors, 42
 Cytology, 245
- D**
 Defecatory dysfunction, 195
 Defecography, 148
 De-novo lipogenesis, 271, 279
 Detoxification, liver, 272
 Diabetes Control and Complications Trial (DCCCT) reference assay, 5
 Diabetes hepatitis, *see* Non-alcoholic fatty liver disease

- Diabetes mellitus (DM), 4, 6–21, 29–41, 48, 149–157, 235
- anorectal function
 - acute hyperglycemia, 156–157
 - diabetic neuropathy, 154–155
 - nitric oxide level, 155–156
 - autoimmune diseases, 50
 - autonomic nervous system
 - DAN, 12–13
 - enteric nervous system, 8
 - extrinsic nervous system, 9, 48
 - food intake and digestion, 11
 - ICC, 9–11
 - neural control, 11
 - parasympathetic, 48
 - sympathetic, 48
 - classification, 3, 41
 - colon
 - clinical manifestations, 149
 - colonic transit time, 153
 - colorectal cancer cells, 153
 - diabetic autonomic neuropathy, 150
 - enteric nervous system, 150–151
 - histomorphological changes, 152
 - interstitial cells of Cajal, 151
 - pathological factors, 150
 - diabetic autonomic neuropathy, 48
 - diabetic complications, 3, 29, 33, 49
 - epidemiology
 - acute metabolic complications, 29
 - atherosclerosis, 31
 - cardiovascular disease, 31
 - diabetic nephropathy, 30
 - diabetic neuropathy, 30, 31
 - diabetic retinopathy, 30
 - macrovascular complications, 29
 - microvascular complications, 29, 30, 32
 - myocardial infarction, 31
 - gastrointestinal complications, 50
 - abnormal manometric findings, 35
 - autonomic neuropathy, 33, 36
 - causes, 34
 - constipation, 36, 37
 - diarrhea, 37
 - esophageal dysmotility, 34
 - functional defects, 34
 - gastroparesis, 35
 - metabolic and anatomic changes, 33
 - NAFLD, 37
 - pathogenesis, 33
 - peripheral neuropathy, 34–35
 - small-intestine and colorectal dysfunctions, 36
 - symptoms, 34
 - gastrointestinal function, 49
 - absorption, 19
 - digestion, 19
 - gastric emptying, 21
 - motility, 19
 - secretion, 20, 21
 - genetic predisposition, 42–44
 - global prevalence, 3, 47
 - gut hormones, 48
 - cholecystokinin, 16
 - gastrin, 15
 - ghrelin, 14, 16
 - GIP, 18
 - GLP-1, 19
 - gut–brain axis, 14, 15
 - incretin, 18
 - NPY, 17
 - PP, 17
 - PYY, 17
 - secretin, 17
 - gut microbiota, 23–25, 49
 - hyperglycemia, 5, 47
 - interstitial cells of Cajal, 48
 - laboratory test, 5, 47, 235
 - metformin, 47
 - morbidity and mortality, 47
 - obesity, 24, 25
 - type 1, 47
 - autoimmune markers, 38, 39
 - incidence, 38
 - LADA, 39
 - pathophysiology, 4
 - prevalence, 38
 - therapeutic approach, 8
 - vs. type 2, 39, 41
 - type 2, 24, 25, 47
 - basal insulin, 6, 7
 - combination injectable therapy, 6
 - empagliflozin, 7
 - incretin-based therapies, 7
 - insulin resistance, 39–41
 - liraglutide, 7
 - metformin, 6
 - obesity, 39
 - pathophysiology, 4
 - pharmacological therapy, 6
 - premixed insulin, 6
 - rapid-acting insulin, 6, 7
 - US, 237
- Diabetic autonomic neuropathy (DAN), 48, 150, 177, 179
- constipation (*see* Constipation)

- diabetes mellitus, 150
 - diarrhea (*see* Diarrhea)
 - degenerative changes, 13
 - etiology, 12
 - gastrointestinal manifestations, 12
 - GI involvement, 12
 - multifactorial etiopathogenetic changes, 13
 - pathogenic mechanisms, 13
 - pathophysiological changes, 13, 164–166
 - peripheral neuropathy, 12
 - Diabetic enteropathy, 37, 137–141, 177
 - causes, 118
 - clinical manifestations, 119–120
 - diagnostic evaluation of, 192
 - functional gastrointestinal disorders, 119
 - pathogenesis, 116
 - prevention, 137
 - treatment
 - constipation, 115, 139
 - delayed intestinal transit, 137
 - diarrhea, 115, 138, 139
 - fecal incontinence, 116, 139
 - GFD, 140, 141
 - L-glutamine supplementation, 138
 - nutritional status, 137
 - psychological status and support, 138
 - Diabetic gastropathy, 35
 - Diabetic ketoacidosis, 70
 - Diabetic microangiopathy, 76
 - Diabetic nephropathy, 30, 49
 - Diabetic neuropathy, 30, 49, 154
 - See also* Diabetic autonomic neuropathy
 - Diabetic retinopathy, 30, 49
 - Diaphragmatic crura, 59
 - Diarrhea, 178–182, 192, 193
 - causes of, 178
 - clinical presentation, 169
 - diagnostic approach
 - evaluation of patient, 179–182
 - fatty diarrhea, 179
 - fecal pH, 178
 - inflammatory diarrhea, 178
 - sudan stain, 179
 - epidemiology, 166–168
 - management
 - antidiarrheal agents, 193
 - antidiarrheal drugs and biofeedback therapy, 193
 - clonidine, 193
 - octreotide, 193
 - supportive care, 192, 193
 - underlying causes of, 193
 - osmotic, 178
 - pathophysiology, 166–169
 - secretory, 178
 - Diffusion/active transport, 105
 - Dipeptidyl peptidase 4 (DPP-4)
 - inhibitor, 6, 7
 - Diphenoxylate, 196
 - Distal contractile integral (DCI), 85
 - Dorsomedial (DMH), 14
 - Dumping syndrome, 74
 - Dyslipidemia, 333
 - Dysmotility, 126
 - Dyspepsia, 87
 - Dysphagia, 84–86
- E**
- Eastern Cooperative Oncology Group (ECOG), 262
 - Efferent sympathetic and parasympathetic pathways, 9
 - Electrogastrography, 88
 - Electrolytes, 108
 - Electromyography (EMG), 148
 - Emulsification, 107
 - Endoanal ultrasonography, 148
 - Endoscopic retrograde
 - cholangiopancreatography (ERCP), 241, 253
 - Endoscopic ultrasound (EUS)
 - calcifications in pancreatic duct, 243
 - CEA, 245
 - cystic lesion, 241, 242
 - EUS-FNA, 241, 243, 244
 - EUS-FNAB, 241
 - EUS-TCB, 241
 - GNAS mutation, 245
 - KRAS gene mutation analysis, 245
 - Rosemont classification of chronic pancreatitis, 242
 - strain ratio analysis of a lesion, 243, 244
 - Endoscopy pancreatic function test (ePFT), 207
 - Enhanced liver fibrosis (ELF), 321
 - Enteric motor neurons, 11
 - Enteric nervous system (ENS), 8–9, 110–112, 147, 150
 - Enteroendocrinology, 113
 - Enterogastric reflexes, 62
 - Eosinophilic esophagitis, 85
 - Esophageal achalasia, *see* Achalasia
 - Esophageal candidiasis, 92
 - Esophageal clearance, 59
 - Esophageal contractility, 85

- Esophageal dysmotility, 34, 56, 85
 asymptomatic, 66
 autonomic neuropathy, 66
 classification, 85
 clinical significance, 67
 esophageal stasis, 67
 esophageal wall function, 66
 esophagogastric outflow obstruction, 91
 manometry, 67
 microvascular damage, 66
 mucosal ulceration, 66
 orally administered medications, 65
 prevalence, 66, 86
 retinopathy, 67
 symptoms, 66
 treatment, 91
- Esophageal microbiome, 59
- Esophageal motor function, 56, 58
- Esophageal musculature, 56
- Esophageal resistance to infection and infestation, 59, 60
- Esophagus
 anatomy, 56
 food bolus, 57
 functions, 55
 smooth muscle cells, 57
- European Society of Medical Oncology (ESMO), 258–260, 263
- EUS-guided fine needle aspiration (EUS-FNA), 241, 243, 244
- EUS-guided fine needle aspiration biopsy (EUS-FNAB), 241
- EUS-guided tissue acquisition (EUS-TA), 241
- EUS-guided trucut biopsy (EUS-TCB), 241
- Evacuation proctography, 148
- Exocrine pancreatic dysfunction, 226
- Exocrine pancreatic function
 evaluation of, 207, 208
 in health, 206, 207
 tests, 235, 236
 in type 1 diabetes, 208–209
 in type 2 diabetes, 209
- Exocrine pancreatic insufficiency (EPI), 133, 227, 228, 236
 absolute or primary, 225
 and DM, 227, 228
 types of, 226
- External anal sphincter (EAS), 146
- Extracorporeal shock-wave lithotripsy (ESWL), 254
- Extrinsic nervous system, 9
- F**
- Fasting plasma glucose value (FPG), 5
- Fatty acids, 270, 271
- Fatty diarrhea, 179
- Fatty liver inhibition of progression (FLIP), 325
- Fecal elastase test, 207
- Fecal incontinence, 139, 185, 186, 196, 197
 clinical presentation, 174
 epidemiology, 172–173
 internal anal sphincter, 184
 management
 biofeedback therapy, 196
 Minimally invasive procedures, 196
 pharmacologic therapy, 196
 supportive measures, 196
 surgical procedures, 197
 pathophysiology, 173–174
 patient evaluation, 185
 anorectal manometry, 186
 balloon expulsion test, 186
 digital rectal examination, 186
 endorectal ultrasound, 186
 endoscopy, 186
 HD-ARM catheters, 186
 HR-ARM catheters, 186
 MR defecography, 186
 physical examination, 185
 rectal contents, 184
- FIB-4 index, 321
- FibroScan elastography, 321
- Fibrosis score, 325
- Fluid depletion, 249
- Fluid resuscitation, 249–250
- FOLFIRINOX, 259, 261, 262
- Food ingestion, 62
- Free fatty acids (FFAs), 107, 271, 279, 285, 286
- Fully-covered self-expandable metal stents (FCSEMS), 255
- Functional dyspepsia, 43
- Functional gastrointestinal disorders, 43
- G**
- G protein-coupled receptors (GPCRs), 17
- Gastric bypass, 331
- Gastric electrical stimulation (GES), 96
- Gastric emptying, 21–22, 88
 assessment, 87
 process, 62
 rate in gastroparesis, 86
 scintigraphic study, 87
- Gastric function assessment, 86
- Gastric motility, 87, 88
 contractile activity, 60
 emptying, 63
 functions, 60
- Gastric motor dysfunction, 86

- Gastric motor physiology
 - activity during fasting, 61
 - electrophysiological properties, 60
- Gastric sensory receptors, 63
- Gastrin, 15
- Gastroesophageal pressure gradient (GEPG), 70
- Gastroesophageal reflux disease, 56
- Gastroesophageal reflux disease (GERD), 58, 59, 85, 86
 - cardinal symptoms, 68
 - definition, 68
 - heartburn, 68
 - occurrence, 68
 - management, 91, 92
 - motor dysfunction, 91
 - pain perception, 68
 - pathogenesis, 68
 - pathophysiology, 69, 70
 - population-based studies, 68
 - prevalence, 68, 69
 - primary care, 69
 - treatment, 92
- Gastrointestinal complications
 - abnormal manometric findings, 35
 - autonomic neuropathy, 33, 36
 - causes, 34
 - constipation, 36, 37
 - diarrhea, 37
 - esophageal dysmotility, 34
 - functional defects, 34
 - gastroparesis, 35
 - metabolic and anatomic changes, 33
 - NAFLD, 37
 - pathogenesis, 33
 - peripheral neuropathy, 35
 - small-intestine and colorectal dysfunctions, 36
 - symptoms, 34
- Gastrointestinal motility disorder, 177
- Gastrointestinal reflexes
 - enteroendocrinology, 113
 - local reflexes, 113
 - long reflexes, 113
 - regional reflexes, 113
- Gastrointestinal system (GI) involvement, 12
- Gastroparesis, 35, 50, 60, 84, 86, 87
 - accelerated gastric emptying, 95
 - acotiamide, 94
 - antiemetic agents, 94
 - clinical trials, 96
 - complications, 71
 - delayed gastric emptying, 72
 - on diabetic control and nutrition, 72
 - diabetic ketoacidosis, 72
 - dietary modification, 93
 - drug therapies, 95
 - economic impact, 73
 - endoscopic pyloromyotomy, 96
 - erythromycin, 94
 - etiologies, 71
 - fluid and electrolyte deficits, 93
 - functional dyspepsia, 72
 - gastrectomy, 96
 - gastric emptying, 74
 - gastric neuromuscular function, 72
 - gastric retention, 72
 - gastrointestinal complications, 71
 - GES implantation, 96
 - glycemic control, 75, 93
 - idiopathic, 72
 - incidence, 73
 - intensive therapy, 72
 - interstitial cells of Cajal, 73
 - itopride, 94
 - management, 93, 95, 96
 - metoclopramide, 93, 94
 - moderate-to-severe pain, 95
 - mosapride, 94
 - natural history, 71
 - nausea, 71, 72
 - neuromuscular dysfunction, 71
 - non-pharmacological approaches, 95
 - nutritional status, 75, 93
 - pathogenesis, 95
 - pathophysiology, 73, 75, 96
 - pharmacological therapy, 93
 - presentation, 71
 - prevalence, 73
 - prognosis, 71
 - psychological distress, 72
 - pyloric dysfunction, 74
 - randomized controlled trials, 96
 - Roux-en-Y gastric bypass, 96
 - symptoms, 72, 75
 - therapeutic approaches, 93
 - treatment algorithm, 93
 - vomiting, 71
 - water load test, 72
- Gemcitabine, 259, 261, 262
- Gemcitabine monotherapy, 262
- Generalized diabetic gastroenteropathy, 67
- Genetic predisposition, 42–44
- GERD-related esophagitis, 85
- Ghrelin, 14, 16, 48
- Glial fibrillary acidic protein (GFAP), 151
- GLP-2 receptor (GLP2R), 19
- Glucagon receptor (CGCR), 19
- Glucagon-like peptide-1 (GLP-1), 19, 48, 280
 - receptor, 6, 7, 19, 333
- Gluconeogenesis, 270

Glucose-dependent insulinotropic peptide (GIP), 48
 Glucose-dependent insulinotropic peptide receptor (GIPR), 19
 Glucose-lowering drugs, 332, 333
 Glutamic acid decarboxylase antibodies (GADA), 4
 Gluten-free diet (GFD), 140, 141
 Glycerol, 270
 Growth hormone-releasing hormone receptor (GHRHR), 19
 Gut hormones
 cholecystokinin, 16, 48
 food intake and energy homeostasis, 48
 gastrin, 15
 ghrelin, 14, 16
 GIP, 18
 GLP-1, 19
 gut-brain axis, 14, 15, 48
 incretins, 18, 48
 NPY, 17, 48
 PP, 17, 48
 PYY, 17, 48
 secretin, 17, 48
 Gut microbiome, 335
 Gut microbiota, 23, 49, 119, 280, 287
 Gut pacemakers, *see* Interstitial cells of Cajal
 Gut-brain axis, 14, 15, 48
 Gut-liver axis, 335

H

Hepatic encephalopathy, 273
 Hepatic insulin resistance, 270
 Hepatic steatosis, 325, 329
 Hepatitis C (HCV) virus, 291, 296, 303, 304
 Hepatocarcinogenesis, 305
 Hepatocellular carcinoma (HCC), 288, 291
 cirrhotic and non-cirrhotic liver, 303, 304
 cumulative incidence of, 291
 genetic factors, 306
 LT, 296
 progression of, 302, 303
 risk factors, 304–306
 surveillance, 292
 Hepatogenous diabetes, 38
 Hepcidin, 271
 High-definition anorectal manometry (HD-ARM)/catheters, 186
 Highly active antiretroviral therapy (HAART), 70
 High-resolution anorectal manometry (HR-ARM)catheters, 186
 High-resolution manometry (HRM), 85

Hounsfield units (HUs), 324
 2-h plasma glucose (2-h PG), 5
 Hyperamylasemia, 234, 235
 Hyperglycemia, 4, 5, 35, 84, 117, 153, 206
 Hypertriglyceridemia, 234
 Hypertrophic pyloric stenosis, 42

I

Ileum, 103
 Immunosuppressive drugs, 299
 Incretin-gut hormones, 206
 Incretins, 18, 48
 Inducible neuronal nitric oxide (iNOS), 43
 Infectious esophagitis, 84
 Inflammatory bowel disease (IBD), 129
 Inflammatory diarrhea, 178
 Inhibitory neurotransmission, 9
 Insulin resistance (IR), 39–41, 279, 284, 285
 Insulin sensitizers, 332
 Insulin therapy, 221, 333
 Insulin-dependent diabetes, *see* Type 1 diabetes
 Insulin-like growth factor-1 (IGF-1), 270
 Integrated relaxation pressure (IRP), 85
 Internal anal sphincter (IAS), 146
 Interstitial cells of Cajal (ICC), 48, 151–152
 basic morphology, 10
 definition, 9
 ICC-MY, 10
 ICC-SEP, 10
 intramuscular ICC, 10
 localization, 10
 multiple functions, 10
 non-glial cells, 9
 non-neuronal cells, 9
 primary function, 10
 slow-wave generation, 11
 Intestinal blood supply, 108–110
 Intestinal function, 103–108, 113
 absorption
 amino acids, 106–107
 lipids, 107
 malabsorption, 107, 108
 maldigestion, 107
 monosaccharides, 106
 nutrients, 103, 105
 paracellular route, 105
 plicae circulares, 105
 secretion, 108
 transcellular route, 105
 water transport, 105
 afferent nociceptive signaling, 112
 enteric nervous system, 110

- gastrointestinal reflexes
 - enteroendocrinology, 113
 - local reflexes, 113
 - long reflexes, 113
 - regional reflexes, 113
 - intestinal blood supply, 108–110
 - motility, 103
 - disorders, 104
 - movement of villi, 104
 - pendular movements, 104
 - peristalsis, 104
 - rhythmic segmentation contractions, 104
 - myenteric (Auerbach's) plexus, 111
 - parasympathetic innervation, 112
 - secretions, 108
 - submucosal (Meissner's) plexus, 111
 - sympathetic innervation, 112
 - water transport, 105
 - Intestinal homeostasis, 62
 - Intestinal hormones, 280
 - Intestinal lymphangiectasia, 130
 - Intestinal lymphoma, 130
 - Intestinal wall remodeling, 165–166
 - Intraductal papillary mucinous neoplasms (IPMN), 245
 - Intramuscular ICC (ICC-IM), 10
 - Iron metabolism, 271
 - Irritable bowel syndrome, 43
- J**
- Jejunum, 103
 - Juvenile-onset diabetes, *see* Type 1 diabetes
- L**
- Lactose hydrogen breath test, 130
 - Lactose intolerance, 130–131
 - Lactose tolerance blood test, 130
 - Laryngopharyngeal reflux (LPR), 69
 - Latent autoimmune diabetes in adults (LADA), 4, 39
 - Lipid metabolism, 270, 271
 - Lipogenesis, 271
 - Lipolysis, 271
 - Liver, 269–272
 - anatomy of, 267, 268
 - bile, 269
 - function, 272
 - bile acid metabolism, 271, 272
 - bilirubin (*see* Bilirubin)
 - carbohydrate metabolism, 270
 - detoxification, 272
 - iron metabolism, 271
 - lipid metabolism, 270, 271
 - protein metabolism, 269
 - lobules, 267
 - NAFLD (*see* Non-alcoholic fatty liver disease)
 - portal venous system, 267, 268
 - unique dual blood supply, 267
 - Liver biopsy, 292, 324–326
 - Liver fibrosis progression, 329
 - Liver steatosis, 284, 318
 - Liver stiffness measurement (LSM), 323
 - Liver transplantation (LT), 277, 289
 - de novo or recurrent NAFLD, 301, 302
 - evaluation for, 296–298
 - indications, 296
 - outcomes, 298, 300, 301
 - recommended follow-up, 300
 - Local reflexes, 113, 147
 - Locally advanced disease, 259–263
 - ASCO rules, 259, 260
 - for metastatic disease, 261, 262
 - NCCN treatment rules, 260
 - palliative care, 262, 263
 - Long reflexes, 113
 - Loperamide, 196
 - Lower esophageal sphincter (LES), 56, 58, 59
 - Low-titer autoantibodies, 320
- M**
- Macrovesicular steatosis, 325
 - Magnetic resonance cholangiopancreatography (MRCP), 239
 - Magnetic resonance elastography (MRE), 292, 324
 - Magnetic resonance imaging (MRI), 239, 324
 - Main pancreatic duct (MPD), 254
 - Malabsorption, 107, 108, 206
 - Maldigestion, 107
 - Mammalian target of rapamycin (mTOR) inhibitors, 300
 - Mediterranean diet, 330, 331
 - Membrane-bound O-acyltransferase (MBOAT7) gene, 306
 - Metabolic memory, 32
 - Metabolic syndrome (MeS), 216, 278, 284, 285, 289, 290, 292, 300, 301, 318, 325
 - adiponectin, 305
 - characterization, 302
 - components of, 282, 284
 - leptin, 305
 - PPHFI, 236
 - prevalence of, 302

- Metastatic disease, 261, 262
 Metformin, 179, 192, 332
 Micelles, 107
 Microvilli, 105
 Migrating motor complex (MMC), 61
 Migratory thrombophlebitis, 224
 Minimally invasive procedures, 196
 Model of end stage liver disease (MELD)
 score, 291
 Modified Marshall Score, 217
 Monoclonal antibody, 335
 Monoglycerides, 107
 Monosaccharides, 106
 Motility disorders, 104
 Multi-hit theory, 285
 Multiple-capsule technique, 183
 Muscularis layer, 104
 Myenteric plexus, 8, 57
- N**
- NAFL, *see* Non-alcoholic fatty liver
 NAFLD, *see* Nonalcoholic fatty liver disease
 NAFLD activity score (NAS), 287, 325, 326
 NAFLD fibrosis score, 325
 National Comprehensive Cancer Network
 (NCCN), 259, 262
 Necrosis, 252
 Necrotizing pancreatitis, 251
 Negative predictive value (NPV), 321
 Neoadjuvant treatment, 259
 Neural control, 11
 Neuroendocrine tumor (NET), 237, 245
 Neuropeptide Y (NPY), 17, 48
 Neurotrophins, 151
 Non-alcoholic fatty liver (NAFL), 277, 317
 adipose tissue, 279
 clinical manifestations, 283
 epidemiology, 278
 pathogenesis, 278
 T1DM, 282
 T2DM, 282
 Non-alcoholic fatty liver disease (NAFLD),
 37–38, 50, 216, 271, 278, 283, 288,
 302–306, 318, 324–326, 329–331
 adipose tissue, role of, 279, 280
 antioxidants, 334
 apoptosis-regulating kinase 1, 335
 bile acid–FXR axis, 334, 335
 characterization, 277
 decreasing dietary fat absorption, 335
 de-novo lipogenesis, 279
 in diabetes mellitus, 329
 diagnosis, 318
 four-pronged diagnostic approach of, 318
 invasive techniques, 324–326
 non-invasive techniques (*see* Non-
 invasive techniques)
 excessive calorie intake, 278
 FFAs, 279
 four-pronged diagnostic approach of, 319
 genetics, role of, 281
 glucose-lowering drugs, 332, 333
 gut microbiota, 280, 281
 gut microbiome, 335
 gut–liver axis, 335
 HCC, 291
 cirrhotic and non-cirrhotic liver, 303,
 304
 genetic factors, 306
 progression of, 302, 303
 risk factors, 304–306
 high prevalence of, 289
 inflammatory chemokine overexpression,
 335
 insulin resistance, 279
 intestinal hormones, 280, 281
 lifestyle and diet, 281
 lipid-lowering agents, 333
 metabolic syndrome, 278
 monoclonal antibody, 335
 NAFL, 277
 clinical manifestations, 283
 epidemiology, 278
 pathogenesis, 278
 NASH (*see* Non-alcoholic steatohepatitis)
 non-pharmacological management
 bariatric surgeries, 331
 lifestyle changes, 329
 mediterranean diet, 330, 331
 regular physical activity, 331
 weight reduction, 331
 pathogenesis of, 286
 patient evaluation, 289
 pharmacological management, 332
 PPAR agonists, 333, 334
 slower fibrosis progression, 290
 spectrum of, 277, 278
 T1DM, 282, 283
 T2DM, 281, 282, 317
 Non-alcoholic fatty pancreas disease
 (NAFPD), 216
 Non-alcoholic steatohepatitis (NASH), 216,
 277, 285, 291, 301
 characterization, 284
 cirrhosis and end-stage liver disease, 284
 clinical manifestation, diagnosis and
 clinical course, 287–289

- CK-18, 320
 - diagnosis, 290, 325
 - epidemiology, 284, 285
 - fibrosis progression rate, 291
 - HCC, 304
 - HCV-related cirrhosis, 291
 - histological diagnosis of, 287
 - LT, 296, 302
 - non-NASH related cirrhosis, 291
 - pathogenesis of, 285–287
 - pentoxifylline, 334
 - serological testing, 320, 321
 - T2DM, 282
- Non-alcoholic steatopancreatitis (NASP), 216
- Noninsulin-dependent diabetes, *see* Type 2 diabetes
- Non-invasive techniques, 320–324
 - imaging technique
 - CT, 323, 324
 - MRI, 324
 - sonoelastography, 323
 - US, 321, 322
 - serological testing
 - advanced fibrosis (< F3), 321
 - aminotransferase levels, 320
 - low-titer autoantibodies, 320
 - NASH, 320, 321
 - serum ferritin levels, 320
 - simple steatosis, 320
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 251
- Nutrition, 251
- O**
- Obesity, 24, 25, 223, 280, 282, 285, 287
 - bariatric surgeries, 331
 - HCC, 305
 - lifestyle and diet, 281
 - LT, 298
 - NAFL, 279
 - T1DM, 282
- Obeticholic acid (OCA), 335
- Octreotide, 193
- Opioids, 251
- Oral glucose tolerance test (OGTT), 5
- Oropharyngeal dysphagia, 85
- Osmosis, 105
- Osmotic and secretory diarrhea, 178
- Osmotic diarrhea
 - characterization, 178
 - vs.* secretory diarrhea, 178
- Oxidative stress, 32
- P**
- p-aminobenzoic acid (PABA)-test, 207
- Pancreatic cancer (PC), 237, 239, 256–259
 - clinical manifestation, 224, 225
 - diagnosis, 237, 239
 - epidemiology, 222
 - EUS, 243
 - limited disease management
 - American Society of Clinical Oncology issued rules, 257
 - characterizing resectability status, 256, 257
 - ESMO, 258, 259
 - NCCN treatment guidelines, 259
 - post-operative proposals, 258
 - preoperative treatment, 257
 - mortality, 222
 - risk factor, 222–224
- Pancreatic diseases, 234, 236–241, 243, 245, 259–263
 - acute pancreatitis (*see* Acute pancreatitis)
 - chronic pancreatitis (*see* Chronic pancreatitis)
 - diagnosis
 - CT, 238, 239
 - EUS, 241, 243, 245
 - MRI and MRCP, 239, 240
 - US, 236–238
 - pancreatic enzyme tests, 234
 - treatment
 - locally advanced disease, 259–263
 - nutrition and physical activity, 263
- Pancreatic duct adenocarcinoma (PDAC), 243
- Pancreatic duct gland (PDG), 216
- Pancreatic elastase, 207
- Pancreatic enzyme replacement therapy, 254
- Pancreatic exocrine insufficiency (PEI), 255, 256
- Pancreatic exocrine replacement therapy (PERT), 256
- Pancreatic neoplasms, 245
- Pancreatic polypeptide (PP), 17, 48, 206
- Pancreatic pseudocysts, 252
- Pancreato-perihepatic fat index (PPHFI), 236
- Paracetamol, 251
- Parasympathetic innervation, 112
- Pelvic floor muscles, 146
- Pentoxifylline, 334
- Peptic ulcer disease (PUD), 75, 76, 96, 97
- Peptide YY (PYY), 17, 48
- Peripheral neuropathy, 12
- Peristalsis, 104
- Peroxisome proliferator-activated receptors (PPAR α) agonists, 333, 334

- Pharmacological therapy, 6
 Phytosterols, 330
 Plioglitazone, 332
 Plicae circulares, 105
 PNPLA3 gene, 285
 Polyphenols, 330
 Poly-unsaturated fatty acids, 330
 Positive predictive value (PPV), 321
 PPI-refractory GERD, 92
 Prague protocol, 85
 Primary liver cancer, *see* Hepatocellular carcinoma
 Proinflammatory microenvironment, 32
 Prokinetics, 93, 94
 Protein metabolism, 269
 Protein tyrosine phosphatase gene PTPN22, 42
 Proton pump inhibitors (PPIs), 92
 Prunes, 194
 Pseudotumor, 237
 Psychological distress, 84
 Pudendal nerve terminal motor latency test (PNTML test), 148, 155
- R**
- Radiopaque markers (ROM), 149
 Reactive oxygenation species (ROS), 32, 216
 Real-time elastography (RTE), 323
 Receptor for advanced glycation end-products (RAGE), 118, 177
 Rectal barostat test, 184
 Rectoanal contractile reflex (RACR), 147
 Rectoanal inhibitory reflex (RAIR), 147
 Regional reflexes, 113
 Renal insufficiency, 234
 Rifaximin, 193
 Rosemont classification system, 242
- S**
- Sacral nerve stimulation (SNS), 197
 Satiety induction, 63
 Secretin, 17, 48
 Secretin receptor (SCTR), 19
 Secretin–pancreozymin test, 208, 209
 Secretory diarrhea, 178
 Sensorimotor response (SMR), 147
 Separate muscle bundles ICC (ICC-SEP), 10
 Serosa, 104
 Serotonin 5-hydroxytryptamine (5-HT), 43
 Simple steatosis, 320
 Single-capsule technique, 183
- Sitagliptin, 333
 Sleeve gastrectomy, 331
 Small intestine, 103–108, 126–133
 anatomy, 103–104
 diagnostic approach
 amyloidosis, 129
 bile salt diarrhea, 133
 celiac disease, 127, 128
 dysmotility, 126
 exocrine pancreatic insufficiency, 133
 infections, 126
 inflammatory bowel disease, 129
 intestinal lymphangiectasia, 130
 intestinal lymphoma, 130
 laboratory testing, 127
 lactose intolerance, 130–131
 small-bowel obstruction, 131
 small-intestine bacterial overgrowth, 133
 tropical sprue, 131, 132
 tumors, 132
 Whipple’s disease, 132
 function (*see* Intestinal function)
 Small-bowel obstruction, 131
 Small-intestine bacterial overgrowth (SIBO), 133, 179, 181
 Sodium glucose transporter 2 (SGLT2) inhibitor, 6, 7
 Sodium pumps, 106
 Sodium–glucose co-transporter 2 inhibitors, 333
 Sonoelastography, 323
 Sphincterotomy, 253
 Sphincteric function, 155
 Stapled transanal rectal resection (STARR), 195
 Statins, 333
 SteatoTest, 320
 Stereotactic body radiotherapy (SBRT), 260
 Stomach
 antrum, 60
 cyclical motor activity, 61
 fed pattern, 62
 food intake, 60
 functions, 60
 gastric motor function, 60
 interstitial cells of Cajal, 61
 proximal stomach, 60
 pylorus, 60
 satiety generation, 60
 tone and phasic contractions, 61
 Stress- and NSAID-induced injury, 76
 Submucosal (Meissner’s plexus), 8

Submucosal layer, 104
 Sulfonyleurea (SU), 6, 7
 Sympathetic innervation, 112
 Systemic inflammatory response syndrome (SIRS), 251

T

Thiazolidinedione (TZD), 6, 7
 Thiazolidinediones, 332
 Tissue resistance, 59
 TM6SF2 gene, 281
 Toll-like receptor-2 (TLR-2) genotype, 43
 Transabdominal ultrasound (US), 236–238
 Transient elastography, 323
 Transient elastography (FibroScan), 322
 Transient elastography (TE), 292
 Transient lower esophageal sphincter relaxation (TLESR), 58
 Transient receptor potential vanilloid 1 (TRPV1), 43
 Triacylglycerol (TAG), 279
 Tropical sprue, 131–132
 Trusseau's syndrome, 224
 Tumor necrosis factor (TNF), 42
 Two-hit theory, 285
 Type 1 diabetes mellitus (T1DM)
 autoimmune markers, 38, 39
 incidence, 38
 LADA, 39
 NAFLD, 282, 283
 prevalence, 38
 vs. type 2, 39, 41
 Type 2 diabetes mellitus (T2DM), 236
 characterization, 216
 EPI, 226
 HCC, 304
 metformin, 332
 diagnosis, 236
 insulin resistance, 39–41
 NAFLD, 281, 282, 317
 NASH, 285

obesity, 39
 regular physical activity, 331
 weight reduction, 331
 Type 3c (pancreatogenic) DM (T3cDM), 227

U

Ultrasonographic fatty liver indicator (US-FLI), 321
 Ultrasonography (US), 321, 322
 Unconjugated bilirubin, 272
 Upper esophageal sphincter (UES), 56, 57
 Upper gastrointestinal dysfunction, 66
 Upper gastrointestinal tract disorders, 42
 Ursodeoxycholic acid, 334

V

Vagally mediated receptive relaxation, 61
 Vascular endothelial growth factor (VEGF), 32
 Vasoactive intestinal polypeptides (VIP), 43
 Ventromedial hypothalamic nucleus (VMH), 14
 Villi, 105
 Virchow's node, 225
 Visceral adipose tissue (VAT) dysfunction, 279
 Vitamin E (tocopherol α), 334

W

Walled-off necrosis (WON), 220, 252
 Water transport, 105
 Whipple's disease, 132
 Wireless motility capsule, 149, 184

X

Xenobiotics, 272, 273

Z

Zollinger–Ellison syndrome, 226